Hodgkins lymphoma
MONDO:0004952A heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.
Also known as: HL, Hodgkin disease, Hodgkin lymphoma, Hodgkin's Disease, Hodgkin's disease, Hodgkin's lymphoma, stage I subdiaphragmatic Hodgkin lymphoma, stage II subdiaphragmatic Hodgkin lymphoma
2204 clinical trials for this condition and its sub-types, 262 tagged with Hodgkins lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hodgkins lymphoma
-
Classic Hodgkin lymphoma 147 trials · 149 incl. sub-types
4 sub-types
-
Nodular lymphocyte predominant Hodgkin lymphoma 5 trials · 6 incl. sub-types
1 sub-type
-
Splenic hodgkin lymphoma 0 trials
-
Double-Drug attack on Hard-to-Treat lymphomas
Disease control Stopped earlyResearchers are testing whether combining two chemotherapy drugs, pralatrexate and romidepsin, is safe and effective for people with lymphoid cancers that have returned or stopped responding to treatment. The trial first finds the highest dose people can tolerate, then gives that…
Phase 1/2 • Sponsor: Jennifer Amengual • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat lymphomas
Disease control Stopped earlyThis study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New lymphoma drug trial halted early
Disease control Stopped earlyThis early-stage study tested a new drug, PF-08046044/SGN-35C, in people with advanced lymphomas (Hodgkin and non-Hodgkin types) who had no other treatment options. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New lymphoma drug trial halted early
Disease control Stopped earlyThis study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Two-Drug combo aims to outsmart resistant hodgkin lymphoma
Disease control Stopped earlyThis phase 2 study tests whether combining magrolimab and pembrolizumab can shrink or eliminate tumors in people with classic Hodgkin lymphoma that has come back or not responded to at least two prior treatments. Magrolimab targets a 'don't eat me' signal on cancer cells, while p…
Phase 2 • Sponsor: Ranjana Advani • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Lymphoma drug combo trial for youth halted after just 5 patients
Disease control Stopped earlyThis early-phase trial tested a combination of two immune-boosting drugs, relatlimab and nivolumab, in children and young adults with Hodgkin or non-Hodgkin lymphoma that had come back or not responded to treatment. The goal was to check safety, drug levels, and whether the tumor…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Mini transplant shows promise for blood cancers – but trial ended early
Disease control Stopped earlyThis study tested a reduced-intensity bone marrow transplant, or 'mini transplant,' for people with blood cancers like lymphoma and leukemia. The transplant used marrow from a relative and was combined with chemotherapy drugs to help the donor cells take hold. Only 15 people took…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Blood cancer transplant study tests safer GVHD prevention
Disease control Stopped earlyThis phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Early trial of experimental cancer combo halted after just 6 patients
Disease control Stopped earlyThis early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New cancer pill tested in humans – but trial halted early
Disease control Stopped earlyThis early-stage trial tested an oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had not responded to prior treatments. The study aimed to find a safe dose and check how the drug moves through the body. However, the trial was terminated, so resul…
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New pill for tough blood cancers tested in early trial
Disease control Stopped earlyThis early-stage study tested an oral drug called AUR104 in 9 adults with certain blood cancers (lymphomas and leukemia) that had come back or stopped responding to treatment. The main goal was to check the drug's safety and how the body processes it. The trial was terminated ear…
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Promising combo trial for lymphoma halted early
Disease control Stopped earlyThis early-stage trial tested a combination of two immune-boosting drugs—pembrolizumab (Keytruda) and CMP-001—in 14 adults with lymphomas that had come back or stopped responding to treatment. The goal was to find a safe dose that could shrink tumors. However, the study was termi…
Phase 1/2 • Sponsor: Umar Farooq • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New pill for tough lymphomas shows early promise, but trial stopped short
Disease control Stopped earlyThis early-stage trial tested an oral drug called HMPL-523 in 69 people with lymphoma that had returned or stopped responding to other treatments. The main goals were to check safety and find the right dose. The study was terminated early, so we have limited information on how we…
Phase 1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New transplant method shows promise for tough blood cancers
Disease control Stopped earlyThis study tested a bone marrow transplant using a partially matched family donor for people with blood cancers like leukemia. The goal was to see if a milder conditioning regimen and a drug called cyclophosphamide could help patients survive at least 180 days after transplant. T…
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo aims to prevent transplant complications in blood cancer patients
Disease control Stopped earlyThis early-phase trial tested whether adding the drug itacitinib to standard immune-suppressing medications could help prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. The study enrolled 84 participants with leukemia, lymphoma,…
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New PET tracer aims to reveal hidden immune activity in tumors and arteries
Diagnosis Stopped earlyThis Phase II study tested a radioactive tracer called 68GaNOTA-Anti-MMR-VHH2 to see if it can light up certain immune cells (macrophages) on PET scans. The trial included 29 people with head and neck cancer, lymphoma, atherosclerosis, or sarcoidosis. The goal was to see if the t…
Phase 2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Blood pressure drug tested to prevent transplant complication
Prevention Stopped earlyThis pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked s…
Sponsor: Hackensack Meridian Health • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC
-
Quick breathing workout tested for lymphoma survivors – but study stalls
Symptom relief Stopped earlyThis study tested whether a simple, 5-minute daily breathing exercise using a handheld device, combined with a personalized exercise plan, could improve heart health and fitness in people who have survived lymphoma. Only one person enrolled before the study was stopped, so no mea…
Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC